SCHEMBL6106065

SCHEMBL6106065

CC(=O)NCCn1cncc1-c1ccnc(Nc2cccc(Cl)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 5/20 0.53
▸ BCR P11274 5/20 0.53
▸ PRKCA P17252 1/20 0.53
▸ PRKCD Q05655 1/20 0.53
▸ CDK2 P24941 4/20 0.49
▸ CAMK2D Q13557 4/20 0.49
▸ CDK4 P11802 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ CCNT1 O60563 1/20 0.45
▸ CDK1 P06493 1/20 0.45
▸ CCNB1 P14635 1/20 0.45
▸ XBP1 P17861 1/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CCND1 P24385 1/20 0.45
▸ CCNE1 P24864 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ MTOR P42345 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ CDK7 P50613 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6595300 0.85 ABL1 (0.53) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL6106058 0.84 ABL1 (0.56) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL6594301 0.83 ABL1 (0.58) ABL1BCRPRKCAPRKCDCDK2
Hydrochloric Acid SCHEMBL6294928 0.82 ABL1 (0.53) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL6594423 0.80 ABL1 (0.62) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL6103563 0.80 ABL1 (0.53) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL27533831 0.78 ABL1 (0.52) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL3602892 0.76 CDK1 (0.58) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL6107317 0.75 CDK1 (0.72) ABL1BCRPRKCAPRKCDCDK2
SCHEMBL3600305 0.74 ABL1 (0.50) ABL1BCRPRKCAPRKCDCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004033-A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation ASTRAZENECA AB 2006-01-05 — — US disclosed
US-6969714-B2 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation ASTRAZENECA AB (SE) 2005-11-29 — — US disclosed
EP-1351958-B1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION ASTRAZENECA AB (SE) 2004-06-16 — — EP disclosed
US-20040014776-A1 Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration ASTRAZENECA AB (SE) 2004-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004033-A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation MKI67, CCNI, CCNT1 ABL1 173/4885BCR 2384/4885PRKCA 1164/4885
US-20040014776-A1 Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration CCNI, TYMP, MKI67 ABL1 822/4885BCR 3765/4885PRKCA 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback